AIM Vaccine Co., Ltd. (06660.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 1.60

From 52W high−65.64%

Volume85000.00

Market capHKD 1.98B

P/E (TTM)—

P/S (TTM)1.7x

Div yield—

Key dataSep 18, 2026

Open

HKD 1.60

From 52W high

−65.64%

Volume

85000.00

Market cap

HKD 1.98B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−61.6x

P/E (TTM)

—

RSI (14)

45.7

MomentumView details →

1D Return

+1.89%

YTD Return

−49.69%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−61.6x

EV/Sales

3.4x

P/S (TTM)

1.7x

P/B (TTM)

0.6x

ProfitabilityView details →

Gross Margin

65.04%

Net Margin

−66.76%

EBITDA Margin

−5.60%

ROE (TTM)

−25.25%

ROA (TTM)

−10.51%

Asset Turnover

0.15x

GrowthView details →

Revenue YoY

−21.05%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−2.67%

EPS CAGR 3Y

—

EBITDA YoY

+35.80%

MomentumView details →

1D Return

+1.89%

YTD Return

−49.69%

1Y Return

−63.04%

RSI (14)

45.7

vs 50D SMA

+0.41%

vs 200D SMA

−36.06%

Capital & dividendView details →

Debt/Equity

0.67x

Current Ratio

0.61x

Quick Ratio

0.49x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.12

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

2.26B

Net Income (TTM)

−934.57M

Op. CF (TTM)

215.73M

Next earningsApr 1, 2027 →

Latest newsMore news →

Aim Vaccine Co., Ltd. announced its interim results for the six months ended June 30, 2026, with revenue of RMB 351 million, down 31.9% year-on-year, and a narrowed net loss of RMB 123 million compared to a loss of RMB 131 million in the same period last year.28d ago

Aimi Vaccine submitted a marketing registration application to China's National Medical Products Administration for its self-developed high-titer human diploid cell rabies vaccine, based on positive Phase III clinical trial results.28d ago

Similar companies

Agios Pharmaceuticals, Inc.AGIO Mesoblast LimitedMESO Rapport Therapeutics, Inc. Common StockRAPP GH Research PLCGHRS ADMA Biologics, Inc.ADMA Vericel CorporationVCEL Find similar companies →

Latest newsMore news →

Aim Vaccine Co., Ltd. announced its interim results for the six months ended June 30, 2026, with revenue of RMB 351 million, down 31.9% year-on-year, and a narrowed net loss of RMB 123 million compared to a loss of RMB 131 million in the same period last year.28d ago Aimi Vaccine submitted a marketing registration application to China's National Medical Products Administration for its self-developed high-titer human diploid cell rabies vaccine, based on positive Phase III clinical trial results.28d ago Aimei Vaccine's wholly-owned subsidiary Aimei Honor submitted supplementary materials to the National Medical Products Administration's Center for Drug Evaluation in response to review comments on the market registration application for its serum-free iterative rabies vaccine.49d ago